Drug
177lu Psma 617
177lu Psma 617: highest development phase Phase 3, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| 177Lu-PSMA-617 NCT04689828 | Phase 3 | Prostatic Neoplasms |
| 177Lu-PSMA-617 NCT04720157 | Phase 3 | Prostatic Neoplasms |
Latest
No recent events.
Follow 177lu Psma 617 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.